Literature DB >> 12457913

Outcome of surgery for bilateral third nerve palsy.

Kazuhiro Aoki1, Tatsushi Sakaue, Nobue Kubota, Toshio Maruo.   

Abstract

PURPOSE: To review the outcome of surgery for bilateral third nerve palsy.
METHODS: The series comprised 16 cases. The eye deviation in the primary position averaged -27.0 degrees horizontally. Surgery was aimed at bringing both eyes into alignment in the primary position by recession-resection of horizontal muscles. Transposition of the superior oblique was performed for complete third nerve palsy. Surgery was initially performed on the nonfixating eye. The fellow eye underwent further surgery for residual disorders.
RESULTS: Within 6 months after surgery, the eye deviation in the primary position averaged -0.7 degrees horizontally. After longer follow-up, the eye deviation averaged -4.7 degrees horizontally. Postoperatively, diplopia in the primary position was absent in 11 and remained in 5 cases.
CONCLUSION: Surgery for bilateral third nerve paresis or palsy achieved lasting cosmetic or functional improvements in the majority of cases.

Entities:  

Mesh:

Year:  2002        PMID: 12457913     DOI: 10.1016/s0021-5155(02)00547-6

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  4 in total

1.  Surgical management of WEBINO syndrome following pineal gland lesion removal.

Authors:  A Toufeeq; D Dave
Journal:  Eye (Lond)       Date:  2013-12-20       Impact factor: 3.775

2.  Extraocular muscle fixation to the orbital wall.

Authors:  Zhale Rajavi
Journal:  J Ophthalmic Vis Res       Date:  2010-04

Review 3.  Periosteal Fixation Procedures in the Management of Incomitant Strabismus.

Authors:  Rohit Saxena; Swati Phuljhele; Pradeep Sharma; C N Pinto
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Jul-Sep

4.  Superior Oblique Anterior Transposition with Horizontal Recti Recession-Resection for Total Third-Nerve Palsy.

Authors:  Muhsin Eraslan; Eren Cerman; Sumru Onal; Mehdi Suha Ogut
Journal:  J Ophthalmol       Date:  2015-11-11       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.